Gene
MKI67
MKI67 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (497), Actionable biomarkers (1), Trial mentions (6), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention MKI67. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 4 at the structurally incomplete recent edge.
MKI67 has 6 trial mentions across 5 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 16 of 11,460 | 0.14% |
| 2022 | 0 of 8,285 | 0.00% | 12 of 13,598 | 0.09% |
| 2021 | 0 of 8,692 | 0.00% | 23 of 15,045 | 0.15% |
| 2020 | 1 of 7,640 | 0.01% | 26 of 14,459 | 0.18% |
| 2019 | 0 of 7,300 | 0.00% | 19 of 12,159 | 0.16% |
| 2018 | 0 of 6,927 | 0.00% | 10 of 11,854 | 0.08% |
| 2017 | 0 of 6,558 | 0.00% | 9 of 11,595 | 0.08% |
Showing 10 of 37 years.
Assay-provider ledger (497)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Agilent | Reagent supplier | Clinical validationAnalytical validation | 4 | July 01, 2026 |
| BioCare Medical, Pacheco, CA | Reagent supplier | Clinical validation | 1 | July 01, 2026 |
| Cancer Diagnostics, Durham, NC | Reagent supplier | Clinical validation | 1 | July 01, 2026 |
| ROCHE DIAGNOSTICS | Context dependent | Clinical validationAnalytical validation | 15 | July 01, 2026 +5 undated |
| SIEMENS | Context dependent | Clinical validationAnalytical validation | 6 | May 22, 2026 |
Showing 5 of 497 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| MKI67 overexpression | SUNITINIB | response-associated | renal carcinoma | Cancer Genome Interpreter |
Trial mentions (6)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT01472445 | Trial outcomes (AACT) |
| NCT00805389 | Trial outcomes (AACT) |
| NCT02801942 | Trial outcomes (AACT) |
| NCT04588298 | Trial outcomes (AACT) |
| NCT06465368 | Trial outcomes (AACT) |
Showing 5 of 6 trial mentions.
Target-disease associations (806)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 22q11.2 deletion syndrome | cardiovascular disease | Mouse knockout (IMPC) |
| ACTH-Producing Pituitary Gland Adenoma | cancer or benign tumor | Literature (Europe PMC) |
| AIDS | genetic, familial or congenital disease | Literature (Europe PMC) |
| AIDS dementia | infectious disease | Literature (Europe PMC) |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
Showing 5 of 806 associations.
Vendor sourcing (10)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.2473T>A (p.S825T) alteration is located in exon 13 (coding exon 12) of the MKI67 gene. This alteration results from a T to A substitution at nucleotide... | View ClinVar record SCV003529331.2 |
| Astrazeneca Plc | Trial sponsor | Mentioned in trial textTrial free-text mention | Antigen KI-67 | View trial NCT04588298 |
| GSK plc | Trial sponsor | Mentioned in trial textTrial free-text mention | MKI67 | View trial NCT00805389 |
| GSK plc | Trial sponsor | Mentioned in trial textTrial free-text mention | Antigen KI-67 | View trial NCT02801942 |
| GeneDx Holdings Corp. | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV001837476.1 |
Showing 5 of 10 sourcing records.
Trial-cited literature (171)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Tumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02). | Signal transduction and targeted therapy | 2025 | 2 |
| Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab. | Therapeutic advances in hematology | 2025 | 2 |
| Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma. | Hepatology (Baltimore, Md.) | 2024 | 88 |
| Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. | Nature medicine | 2024 | 60 |
| Biomarkers in Cancer Detection, Diagnosis, and Prognosis. | Sensors (Basel, Switzerland) | 2023 | 222 |
Showing 5 of 171 papers.
Protein variant mentions (3)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.K27M | 1 | 2015 | PMID 25749048 |
| p.P921F | 1 | 2018 | PMID 29474450 |
| p.R921F | 1 | 2018 | PMID 29474450 |
Literature-extracted relations (4)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| ADALIMUMAB | Chemical | negative_correlate |
Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis. | 2009 |
| Breast Neoplasms | Disease | associate |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). | 2017 |
| Dermatitis, Atopic | Disease | associate |
RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. | 2015 |
| Lymphoma, B-Cell | Disease | associate |
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). | 2008 |
Organizations publishing (244)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Lund University | Academic | 8 | 2014 to 2023 |
| Dana-Farber Cancer Institute | Other | 7 | 2016 to 2025 |
| Harvard Medical School | Academic | 7 | 2016 to 2025 |
| Memorial Sloan Kettering Cancer Center | Hospital | 7 | 2015 to 2022 |
| University of North Carolina System | Academic | 6 | 2011 to 2020 |
Showing 5 of 244 organizations.
Where MKI67 appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
792 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.